Authors:
Thigpen, T
Brady, MF
Homesley, HD
Soper, JT
Bell, J
Citation: T. Thigpen et al., Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma:A gynecologic oncology group study, J CL ONCOL, 19(2), 2001, pp. 364-367
Citation: Pm. Fracasso et al., Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovariancarcinoma: A gynecologic oncology group study, J CL ONCOL, 19(12), 2001, pp. 2975-2982
Authors:
Zaino, R
Whitney, C
Brady, MF
DeGeest, K
Burger, RA
Buller, RE
Citation: R. Zaino et al., Simultaneously detected endometrial and ovarian carcinomas - A prospectiveclinicopathologic study of 74 cases: A gynecologic oncology group study, GYNECOL ONC, 83(2), 2001, pp. 355-362
Authors:
Muggia, FM
Braly, PS
Brady, MF
Sutton, G
Niemann, TH
Lentz, SL
Alvarez, RD
Kucera, PR
Small, JM
Citation: Fm. Muggia et al., Phase III randomized study of cisplatin versus paclitaxel versus cisplatinand paclitaxel in patients with suboptimal stage III or IV ovarian cancer:A gynecologic oncology group study, J CL ONCOL, 18(1), 2000, pp. 106-115
Authors:
Berek, JS
Bertelsen, K
du Bois, A
Brady, MF
Carmichael, J
Eisenhauer, EA
Gore, M
Grenman, S
Hamilton, TC
Hansen, SW
Harper, PG
Horvath, G
Kaye, SB
Luck, HJ
Lund, B
McGuire, WP
Neijt, JP
Ozols, RF
Parmar, MKB
Piccart-Gebhart, MJ
van Rijswijk, R
Rosenberg, P
Rustin, GJS
Sessa, C
Thigpen, JT
Trope, C
Tuxen, MK
Vergote, I
Vermorken, JB
Willemse, PHB
Citation: Js. Berek et al., Advanced epithelial ovarian cancer: 1998 consensus statements, ANN ONCOL, 10, 1999, pp. 87-92
Authors:
Thigpen, JT
Brady, MF
Alvarez, RD
Adelson, MD
Homesley, HD
Manetta, A
Soper, JT
Given, FT
Citation: Jt. Thigpen et al., Oral medroxyprogesterone acetate in the treatment of advanced or recurrentendometrial carcinoma: A dose-response study by the Gynecologic Oncology Group, J CL ONCOL, 17(6), 1999, pp. 1736-1744